Literature DB >> 23255200

Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance.

Asha R Srinivasan1, Sunday A Shoyele.   

Abstract

The ability to produce submicron particles of monoclonal antibodies of different sizes and shapes would enhance their application to pulmonary delivery. Although non-ionic surfactants are widely used as stabilizers in protein formulations, we hypothesized that non-ionic surfactants will affect the shape and size of submicron IgG particles manufactured through precipitation. Submicron particles of IgG1 were produced by a precipitation process which explores the fact that proteins have minimum solubility but maximum precipitation at the isoelectric point. Non-ionic surfactants were used for size and shape control, and as stabilizing agents. Aerosol performance of the antibody nanoparticles was assessed using Andersen Cascade Impactor. Spinhaler® and Handihaler® were used as model DPI devices. SEM micrographs revealed that the shape of the submicron particles was altered by varying the type of surfactant added to the precipitating medium. Particle size as measured by dynamic light scattering was also varied based on the type and concentration of the surfactant. The surfactants were able to stabilize the IgG during the precipitation process. Polyhedral, sponge-like, and spherical nanoparticles demonstrated improved aerosolization properties compared to irregularly shaped (>20 μm) unprocessed particles. Stable antibody submicron particles of different shapes and sizes were prepared. Careful control of the shape of such particles is critical to ensuring optimized lung delivery by dry powder inhalation.

Mesh:

Substances:

Year:  2012        PMID: 23255200      PMCID: PMC3581634          DOI: 10.1208/s12249-012-9913-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  33 in total

Review 1.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

Review 2.  Nanoparticle formulations in pulmonary drug delivery.

Authors:  Mark M Bailey; Cory J Berkland
Journal:  Med Res Rev       Date:  2009-01       Impact factor: 12.944

3.  Lyophilization and enhanced stability of fluorescent protein nanoparticles.

Authors:  Kyung Rim Kim; Keum-Young Ahn; Jin-Seung Park; Kyung Eun Lee; Hyesung Jeon; Jeewon Lee
Journal:  Biochem Biophys Res Commun       Date:  2011-03-30       Impact factor: 3.575

4.  The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody.

Authors:  J D Andya; Y F Maa; H R Costantino; P A Nguyen; N Dasovich; T D Sweeney; C C Hsu; S J Shire
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

5.  Linolenic acid-modified chitosan for formation of self-assembled nanoparticles.

Authors:  Chen-Guang Liu; Kashappa Goud H Desai; Xi-Guang Chen; Hyun-Jin Park
Journal:  J Agric Food Chem       Date:  2005-01-26       Impact factor: 5.279

Review 6.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.

Authors:  J L Cleland; M F Powell; S J Shire
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1993       Impact factor: 4.889

7.  Detergent-assisted refolding of guanidinium chloride-denatured rhodanese. The effects of the concentration and type of detergent.

Authors:  S Tandon; P M Horowitz
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

8.  Acid-catalyzed peptide bond hydrolysis of recombinant human interleukin 11.

Authors:  R A Kenley; N W Warne
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

9.  Degradation pathways for recombinant human macrophage colony-stimulating factor in aqueous solution.

Authors:  J A Schrier; R A Kenley; R Williams; R J Corcoran; Y Kim; R P Northey; D D'Augusta; M Huberty
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

Review 10.  Therapeutic nanoparticles for drug delivery in cancer.

Authors:  Kwangjae Cho; Xu Wang; Shuming Nie; Zhuo Georgia Chen; Dong M Shin
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

View more
  3 in total

Review 1.  Nanoparticle-mediated pulmonary drug delivery: a review.

Authors:  Mukta Paranjpe; Christel C Müller-Goymann
Journal:  Int J Mol Sci       Date:  2014-04-08       Impact factor: 5.923

2.  Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.

Authors:  Maryna Perepelyuk; Christina Maher; Ashakumary Lakshmikuttyamma; Sunday A Shoyele
Journal:  Int J Nanomedicine       Date:  2016-07-28

3.  Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation.

Authors:  Nneka Dim; Maryna Perepelyuk; Olukayode Gomes; Chellappagounder Thangavel; Yi Liu; Robert Den; Ashakumary Lakshmikuttyamma; Sunday A Shoyele
Journal:  J Nanobiotechnology       Date:  2015-09-26       Impact factor: 10.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.